International Journal of Clinical Research

As the most common chronic ocular surface disease in clinical practice, dry eye syndrome is characterized by unstable tear film and damage to the ocular surface, which are related to abnormal tear quality, quantity, or dynamics, leading to discomfort in the eyes. At present, the incidence rate of dry eye is gradually rising, causing increased attention to it. Traditional treatment methods mainly focus on relieving symptoms by replacing tears and maximizing the retention of intraocular tears, but fail to address the underlying causes. With the increasing understanding of the pathology of dry eye syndrome, many new treatment methods have been proposed. The main medication for treating dry eye syndrome is artificial tear eye drops, and auxiliary treatment can use non steroidal anti-inflammatory drugs and corticosteroids to alleviate discomfort in dry eye syndrome. Immunosuppressants can be an effective choice for long-term medication for dry eye syndrome. In addition, autologous serum and dexamethasone tetrasodium are widely recognized and have good development prospects.

Dry eye syndrome; Drug therapy; New developments; Artificial tears